<DOC>
	<DOCNO>NCT01037842</DOCNO>
	<brief_summary>We perform prospective , randomize , multicenter trial ass efficacy safety combine treatment mitiglinide metformin patient type 2 diabetes show inadequate glycemic control metformin monotherapy . Subjects HbA1c &gt; 7.0 % 8-week metformin run-in phase randomize 16-week trial phase metformin plus mitiglinide ( Met+Mit ) metformin plus placebo ( Met ) .</brief_summary>
	<brief_title>Effect Combination Mitiglinide Metformin Glycemic Control Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This 16-week , randomize , double-blind study compare metformin plus mitiglinide ( Met+Mit ) versus metformin plus placebo ( Met+Pcb ) . An 8-week metformin run-in phase ( 500 mg twice day first 4 week 500 mg three time day follow 4 week ) follow 16-week trial phase ( mitiglinide 10 mg placebo three time day add metformin 500 mg three time day ) . The subject HbA1c &gt; 7.0 % end metformin run-in phase randomize Met+Mit group Met+Pcb group trial phase .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>age 3070 year duration diabetes &lt; 10 year body mass index ( BMI ) 2035 kg/m2 plasma HbA1c level 7.511 % previous 4 week subject diagnose type 1 diabetes , gestational diabetes , diabetes specific cause Subjects treat nateglinide , repaglinide , metformin ( 1,000 mg/day ) , sulfonylurea ( quarter maximum recommend dose ) previous 8 week</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>